Trial Search Results

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

The purpose of the ATLAS study is to determine how patients with locally advanced or metastatic urothelial carcinoma respond to treatment with rucaparib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator: Foundation Medicine

Stanford Investigator(s):


  • Drug: Rucaparib


Phase 2


Inclusion Criteria:

   - Have histologically or cytologically confirmed locally advanced unresectable or
   metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter,
   urinary bladder or urethra)

   - Received 1 or 2 prior treatment regimens for advanced or metastatic disease

   - Confirmed radiologic disease progression during or following recent treatment

   - Mandatory biopsy is required during screening

   - Measurable disease per RECIST v1.1

   - Adequate organ function

   - ECOG 0 or 1

Exclusion Criteria:

   - Prior treatment with a PARP inhibitor

   - Symptomatic and/or untreated CNS metastases

   - Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
   of rucaparib

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting